NICM
UTHR icon

Neo Ivy Capital Management’s United Therapeutics UTHR Stock Holding History

Neo Ivy Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-205
Closed -$48K – 562
2022
Q2 		$48K Buy
+205
New +$41.7K 0.13% 241
2020
Q2 		– Sell
-16
Closed -$2K – 607
2020
Q1 		$2K Buy
+16
New +$1.52K ﹤0.01% 442

Other funds holding UTHR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Neo Ivy Capital Management's UTHR Position: Q3 2022 in Review

Neo Ivy Capital Management sold out of United Therapeutics (UTHR) in Q3 2022, closing a stake of 205 shares — an estimated $48K sold.

Neo Ivy Capital Management first reported a position in UTHR in Q1 2020 and held it in 2 quarters. The position peaked at $48K in Q2 2022. 459 funds tracked by Wall St. Rank hold UTHR as of Q3 2022.

  • Neo Ivy Capital Management reported no remaining United Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Neo Ivy Capital Management sold 205 United Therapeutics shares in Q3 2022, an estimated $48K.
  • Neo Ivy Capital Management first reported a position in United Therapeutics in Q1 2020 and held it in 2 quarters.
  • Neo Ivy Capital Management's United Therapeutics position peaked at $48K in Q2 2022.
  • 459 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2022.

Based on Neo Ivy Capital Management's 13F filing for Q3 2022, filed 16 Nov 2022.